SelPac logo

SelPac

A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in Metastatic Uveal Melanoma

SelPac

A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in Metastatic Uveal Melanoma
Funding AstraZeneca (AZ)
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status In Follow-up
Start Date 26-Aug-2015

This trial is looking at selumetinib and paclitaxel for a type of eye cancer called uveal melanoma. It is for people whose uveal melanoma has spread elsewhere in the body. This trial is supported by Cancer Research UK.

Selumetinib is a type of biological therapy. It works by targeting a protein called MEK (so it is called a MEK inhibitor) MEK is a protein that sends signals to cells telling them to divide and grow.

Previous trials have shown that selumetinib may help to treat uveal melanoma that has spread. Very early research in the laboratory suggests that using selumetinib alongside a chemotherapy drug called paclitaxel may improve treatment.

The aim of the trial is to see if selumetinib and paclitaxel works better than selumetinib alone for uveal melanoma. The researchers will also try to find the best way to give these 2 drugs together.

Publications

  • P Nathan, A Needham, P G Corrie, S Danson, J Evans, S Ochsenreither, S Kumar, A Goodman, J M G Larkin, I Karydis, N M Steven, P Lorigan, R Plummer, P Patel, H M Shaw, S Leyvraz, C Rawcliffe, E E Psarelli, L Handley, J J Sacco, LBA73 SELPAC: A 3 arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM), Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz394.070, https://doi.org/10.1093/annonc/mdz394.070
    1. Annals of Oncology, Volume 30, Issue Supplement_5, October 2019, mdz394.070, https://doi.org/10.1093/annonc/mdz394.070